Latest Blood pump Stories
NEW YORK, Aug. 14, 2012 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced full FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000® heart for destination therapy (DT) named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD Effectiveness). (Photo: http://photos.prnewswire.com/prnh/20120227/NY60355 ) Use of the device for DT means that it will provide long-term, permanent...
First patient successfully receives donor heart. Second patient on Freedom Driver. NORFOLK, Va., March 6, 2012 /PRNewswire-USNewswire/ -- Living without a heart. What was once only a far off concept has now become a reality for advanced heart failure patients in need of more time to await a heart transplant. (Photo: http://photos.prnewswire.com/prnh/20120306/DC65557) Physicians at Sentara Heart Hospital have begun offering the Total Artificial Heart (TAH) as the latest...
NEW YORK, Feb. 27, 2012 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced conditional FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000® heart for destination therapy (DT). Use of the device for DT means that it will provide long-term, permanent support to end-stage congestive heart failure patients who are not candidates for heart transplant. The approval permits fifty medical centers to...
SILVER SPRING, Md., Dec. 16, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a medical device that supports the weakened heart of children with heart failure to help keep them alive until a donor for a heart transplant can be found. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The mechanical pulsatile cardiac assist device is called the EXCOR Pediatric System, made by a German company, Berlin Heart. The device comes in graduated sizes to...
LOUISVILLE, Ky., Sept. 9, 2011 /PRNewswire/ -- Data presented today at the 19th Congress of the International Society for Rotary Blood Pumps (ISRBP) demonstrated that the HeartWare MVAD(®) Pump attained the objectives for system performance, hemocompatability and biocompatibility in Good Laboratory Practice (GLP) animal studies, a significant step prior to commencement of human clinical studies. (Photo: http://photos.prnewswire.com/prnh/20110909/LA65433) HeartWare's MVAD Pump is a...
PLEASANTON, Calif., Aug. 3, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has acquired the medical business of Levitronix LLC ("Levitronix Medical") for an upfront cash payment of $110 million, as well as potential future cash earnout payments of up to $40 million. This transaction solidifies Thoratec's position as the leading, full-line...
ANN ARBOR, Mich., July 19, 2011 /PRNewswire/ -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that a patient implanted with the DuraHeart(TM) Left Ventricular Assist System (LVAS) has surpassed five years of support on the mechanical circulatory support device. Helga Gieseke, living in Germany, was treated at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) and is now one of the longest-living heart failure recipients of the...
Device Provides Support for Those Who Are Not Acceptable Transplant Candidates SILVER SPRING, Md., Jan. 20 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the HeartMate II, a continuous-flow, left ventricular assist system as a support for severe heart failure patients who are not acceptable candidates for heart transplantation. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The HeartMate II is already FDA-approved for use in patients awaiting...
SALT LAKE CITY, Nov. 17 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that it has finalized assignment and exclusive license agreements with LaunchPoint Technologies Inc., (LPT) Goleta, California, and Carnegie Mellon University (CMU), Pittsburgh, Pennsylvania for its next-generation minimally invasive blood pump, the MiVAD. The MiVAD(TM) is designed to provide partial cardiac support between 2-4 liters per minute to less sick...
Study highlights: -- Continuous flow heart pump improved survival better than pulsating pump for heart failure patients ineligible for transplant. -- The new, continuous flow left ventricular assist device is smaller, quieter and more durable than pulsating models. ORLANDO, Fla., Nov. 17 /PRNewswire-USNewswire/ -- A new, continuous flow heart pump, or left ventricular assist device (LVAD), delivered better two-year survival in advanced heart failure patients than the current pulsatile...
